Urethral Stricture Treatment Market, By Type (Posterior Urethral Stricture, Anterior Urethral Stricture), By Treatment (Urethral Dilation, Direct Vision Internal Urethrotomy (DVIU), Urethroplasty (Anastomotic Urethroplasty, Substitution Urethroplasty), Ot

Urethral Stricture Treatment Market, By Type (Posterior Urethral Stricture, Anterior Urethral Stricture), By Treatment (Urethral Dilation, Direct Vision Internal Urethrotomy (DVIU), Urethroplasty (Anastomotic Urethroplasty, Substitution Urethroplasty), Others), By Disease Indication (Latrogenic, Idiopathic, Infection-induced, Trauma, Others), By End User (Hospitals, Ambulatory Surgical Centers, Others), By Region (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Urethral stricture is the narrowing of the calibre of the urethra that is caused due to scarring resulting from infection or injury. There are two types of urethral strictures named posterior urethral stricture and anterior urethral stricture. Posterior urethral strictures occur due to fibrosis of the posterior urethra or distraction injuries that result from trauma or pelvic fractures. Anterior urethral stricture are the most commonly occurring strictures, and are caused due to infection or trauma leading to spongiofibrosis. The condition can be treated with various treatment options such as urethral direct vision internal urethrotomy (DVIU), urethroplasty, and other treatments. The main symptoms of urethral stricture are obstructed and irritated micturition, with increased urination time, and a feeling of incomplete bladder emptying. Its prevalence among men in industrial countries is estimated at 0.9%. It produces obstructive and irritative urinary symptoms, and can ultimately impair renal function. Urethral strictures can be caused by diagnostic or therapeutic urological procedures. These procedures are being performed more commonly, because the population is aging, and thus, urethral strictures will probably become more common as well.

Market Dynamics

Increasing adoption of inorganic growth strategies such as approvals by the regulatory authorities in the market to expand their product portfolio, is expected to drive the market growth over the forecast period. For instance, in January 2022, Laborie., a medical technology company thath provide products for urology, gynecology, and others, announced that it has received a license to the Optilume, a urethral drug coated balloon (DCB), laborite., and product is approved from U.S. Food and Drug Administration (FDA).

Key features of the study:

• This report provides in-depth analysis of the global urethral stricture treatment market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global urethral stricture treatment market based on the following parameters–company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study are Becton, Dickinson and Company, Amecath, Zhejiang Chuangxiang, Medical Technology Co., Ltd, Allium Ltd., SURGIMEDIK, Cook Group, Taewoong Medical Co., Ltd., Teleflex Incorporated, B. Braun Melsungen AG, Coloplast A/S, Boston Scientific Corporation, and Pnn Medical A/S. , and Laborie.Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global urethral stricture treatrment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global urethral stricture treatment market

Detailed Segmentation:

• Global Urethral Stricture Treatment Market, By Type:
• Posterior Urethral Stricture
• Anterior Urethral Stricture
• Global Urethral Stricture Treatment Market, By Treatment:
• Urethral Dilation
• Direct Vision Internal Urethrotomy (DVIU)
• Urethroplasty
• Anastomotic Urethroplasty
• Substitution Urethroplasty
• Others
• Global Urethral Stricture Treatment Market, By Disease Indication:
• Latrogenic
• Idiopathic
• Infection-induced
• Trauma
• Others
• Global Urethral Stricture Treatment Market, By End User:
• Hospitals
• Ambulatory Surgical Centers
• Others
• Global Urethral Stricture Treatment Market, By Region:
• North America
• By Country:
• U.S.
• Canada
• Latin America
• By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country:
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country:
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country/Region:
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Becton, Dickinson and Company*
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Amecath
• Zhejiang Chuangxiang
• Medical Technology Co., Ltd
• Koninklijke Philips N.V.
• Allium Ltd.
• SURGIMEDIK
• Cook Group
• Taewoong Medical Co., Ltd.
• Teleflex Incorporated
• Braun Melsungen AG
• Coloplast A/S
• Boston Scientific Corporation
• Pnn Medical A/S

“*” marked represents similar segmentation in other categories in the respective section.